Trade

with

Celgene Corp
(NASDAQ: CELG)
US Markets Closed
AdChoices
94.76
-0.21
-0.22%
After Hours :
93.95
-0.81
-0.85%

Open

94.93

Previous Close

94.97

Volume (Avg)

8.72M (4.50M)

Day's Range

93.82-96.85

52Wk Range

66.85-96.85

Market Cap.

75.93B

Dividend Rate ( Yield )

-

Beta

1.10

Shares Outstanding

799.51M

P/E Ratio (EPS)

54.95 (1.73)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 6.49B

    • Net Income

    • 1.45B

    • Market Cap.

    • 75.93B

    • Enterprise Value

    • 76.65B

    • Net Profit Margin %

    • 20.82

    • PEG (Price/Earnings Growth) Ratio

    • 0.75

    • Beta

    • 1.10

    • Forward P/E

    • 19.12

    • Price/Sales

    • 11.45

    • Price/Book Value

    • 15.65

    • Price/Cash flow

    • 35.59

      • EBITDA

      • 2.13B

      • Return on Capital %

      • 10.62

      • Return on Equity %

      • 28.55

      • Return on Assets %

      • 10.62

      • Book Value/Share

      • 6.07

      • Shares Outstanding

      • 799.51M

      • Last Split Factor (Date)

      • 2:1 (6/26/2014)

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 106.00

        • Credit Rating

        • A

        • Analysts

        • 8

        • EPS Estimate

        • 4.45

        • Cashflow Estimate

        • 5.32

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 17.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -0.40

          • 17.04

          • Net Income

            Q/Q (last year)

          • 25.00

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 23.56

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 94.82

            • 82.75

            • Pre-Tax Margin

            • 24.15

            • 39.38

            • Net Profit Margin

            • 20.82

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 92.80

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 29.90

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 25.80

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 1.39

              • 0.76

              • Current Ratio

              • 5.44

              • 2.92

              • Quick Ratio

              • 4.92

              • 2.35

              • Interest Coverage

              • 14.59

              • 38.02

              • Leverage Ratio

              • 3.22

              • 2.21

              • Book Value/Share

              • 6.07

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 53.19

                • 196.08

                • P/E Ratio 5-Year High

                • 55.92

                • 634.30

                • P/E Ratio 5-Year Low

                • 13.91

                • 124.82

                • Price/Sales Ratio

                • 11.10

                • 9.12

                • Price/Book Value

                • 15.15

                • 8.26

                • Price/Cash Flow Ratio

                • 35.59

                • 47.39

                • Key Metrics

                • Company

                  • Shares Short

                    as of 9/30/2014

                  • 11.75M

                  • Short Ratio

                    as of 9/30/2014

                  • 2.75

                  • Short % of Float

                    as of 9/30/2014

                  • 1.47

                  • Shares Short

                    prior month

                  • 12.07M

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • 2:1

                    • Last Split Date

                    • 6/26/2014

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • 28.55

                        (22.30)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • 10.62

                        (13.00)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • 15.11

                        (17.30)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • 287.14k

                      • 117.08k

                      • Inventory Turnover

                      • 1.11

                      • 1.48

                      • Asset Turnover

                      • 0.51

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      1.81B
                      Operating Margin
                      27.86
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      35.59
                      Ownership

                      Institutional Ownership

                      84.95%

                      Top 10 Institutions

                      26.08%

                      Mutual Fund Ownership

                      43.73%

                      Float

                      99.76%

                      5% / Insider Ownership

                      0.37%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard Total Stock Mkt Idx

                      •  

                        13,070,312

                      • 0.65

                      • 1.63

                      • Vanguard Five Hundred Index Fund

                      •  

                        8,300,209

                      • 0.07

                      • 1.04

                      • Vanguard Institutional Index Fund

                      •  

                        8,099,811

                      • -1.22

                      • 1.01

                      • SPDR® S&P 500 ETF

                      •  

                        7,812,541

                      • -2.11

                      • 0.95

                      • PowerShares QQQ

                      •  

                        6,541,150

                      • -1.08

                      • 0.82

                      • MainStay Large Cap Growth Fund

                      •  

                        6,443,400

                      • -0.31

                      • 0.81

                      • CREF Stock

                      •  

                        5,523,601

                      • 0.63

                      • 0.69

                      • Harbor Capital Appreciation Fund

                      •  

                        5,397,468

                      • 15.60

                      • 0.68

                      • Hansard EU Carmignac Patrimoine

                      •  

                        5,360,230

                      • 0.00

                      • 0.67

                      • T. Rowe Price Blue Chip Growth Fund

                      •  

                        5,143,100

                      • 101.31

                      • 0.64

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard Group, Inc.

                      •  

                        41,041,607

                      • -0.47%

                      • 5.14

                      • State Street Corp

                      •  

                        32,736,102

                      • -1.78%

                      • 4.10

                      • T. Rowe Price Associates, Inc.

                      •  

                        26,649,341

                      • +0.95%

                      • 3.33

                      • BlackRock Fund Advisors

                      •  

                        25,233,186

                      • -1.40%

                      • 3.16

                      • J.P. Morgan Investment Management Inc.

                      •  

                        17,349,765

                      • +3.94%

                      • 2.17

                      • Jennison Associates LLC

                      •  

                        14,530,799

                      • +22.59%

                      • 1.82

                      • Janus Capital Management LLC

                      •  

                        12,837,413

                      • -4.00%

                      • 1.60

                      • Columbia Mangmt Investment Advisers, LLC

                      •  

                        12,688,658

                      • +6.66%

                      • 1.59

                      • Winslow Capital Management, LLC

                      •  

                        10,877,890

                      • -5.44%

                      • 1.36

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Aggressive Growth

                      Style

                      Large Growth

                      Celgene Corp is incorporated in Delaware. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related di...moreseases. The Company is engaged in new research and development designed to bring new therapies to market and we are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company’ commercial stage products include REVLIMID(r), VIDAZA(r), ABRAXANE(r), POMALYST(r)/IMNOVID(r), THALOMID(r) (inclusive of ...moreThalidomide CelgeneTM), ISTODAX(r) and azacitidine for injection (generic version of VIDAZA(r)). The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.lessless

                      Key People

                      Perry A. Karsen

                      CEO, Divisional/Executive VP

                      Robert J. Hugin

                      CEO/Chairman of the Board/Director

                      Peter N. Kellogg

                      Executive VP/CFO

                      Lawrence Stein

                      Executive VP/General Counsel/Secretary

                      Mr. Thomas O. Daniel

                      Executive VP/President, Divisional

                      • Celgene Corp

                      • 86 Morris Avenue

                      • Summit, NJ 07901

                      • USA.Map

                      • Phone: +1 908 673-9000

                      • Fax: +1 908 673-9001

                      • celgene.com

                      Incorporated

                      0

                      Employees

                      5,100

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: